Subpopulation analysis shows first-of-its-kind findings in HNSCC, with reduced HPV viral load and a gigaxonin-linked mechanism suggesting lower metastatic risk.
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Hema Gandhi
Aveta Biomics Announces Podium Presentation of Registrational Phase 3 Head and Neck Cancer Trial at AHNS 2026 Conference
Global Phase 3 study of first oral immunotherapy designed to work independent of PD-L1 across “hot” and “cold” tumors in locally advanced head and neck cancer BEDFORD, MA, UNITED STATES, March 24, 2026 / EINPresswire.com/ -- Aveta Biomics, a clinical stage biotechnology company developing first-in-class therapies designed to reprogram the immune system to fight cancer, today announced that its Trial-in-Progress abstract for the registrational Phase 3 study of APG-157 in head and neck squamous...
Aveta Biomics to Present at the Upcoming 2025 ESMO Congress
ESMO data illuminate APG-157’s immune-modulating mechanism in Head and Neck Cancer ahead of the upcoming Phase 3 trial and its broad therapeutic potential BEDFORD, MA, UNITED STATES, October 13, 2025 /EINPresswire.com/ -- Aveta Biomics, a clinical-stage biotechnology company developing first-in-class drugs that reprogram the immune system to fight cancer, today announced the poster presentation of new clinical and translational findings from its Phase IIa study of APG-157 at the European...
Aveta Biomics Announces Abstract Acceptance for Presentation at the 2025 ASCO Annual Meeting
Aveta Biomics Announces Abstract Acceptance for Presentation at the 2025 ASCO Annual Meeting Aveta Biomics to present the results from Phase 2A trial of APG-157 as neoadjuvant monotherapy for head and neck cancer at ASCO 2025.
GenAI: Top 5 Use Cases in Investment Banking
Welcome to Finextra. We use cookies to help us to deliver our services. We'll assume you're ok with this, but you may change your preferences at our Cookie Centre. Please read our Privacy Policy. News in your inbox For Finextra's free daily newsletter, breaking news and flashes and weekly job board. Sign Up Channels Group External | what does this mean? This content is provided by an external author without editing by Finextra. It expresses the views and opinions of the author.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Hema
Contact Hema, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack